These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10204617)

  • 1. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha.
    Kobayashi M; Chayama K; Arase Y; Tsubota A; Saitoh S; Suzuki Y; Kobayashi M; Kobayashi M; Ikeda K; Matsuda M; Koike H; Hashimoto M; Kumada H
    J Gastroenterol; 1999 Feb; 34(1):94-9. PubMed ID: 10204617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
    Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype.
    Chayama K; Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    J Virol Methods; 2001 Jun; 95(1-2):33-45. PubMed ID: 11377711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus.
    Hayashi J; Kawakami Y; Nabeshima A; Kishihara Y; Furusyo N; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1998 Feb; 43(2):384-91. PubMed ID: 9512135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.
    Soffredini R; Rumi MG; Del Ninno E; Parravicini ML; Russo A; Colombo M
    J Viral Hepat; 1999 Jan; 6(1):65-71. PubMed ID: 10847132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C.
    Walsh KM; Good T; Cameron S; Thorburn D; McCruden EA; Mills PR; Morris AJ
    Liver; 1998 Jun; 18(3):191-5. PubMed ID: 9716230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay.
    Nomura H; Kimura Y; Rikimaru N; Tada H; Okamoto O; Shiraishi G; Kashiwagi S
    J Infect; 1997 May; 34(3):249-55. PubMed ID: 9200033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype.
    Kobayashi M; Kumada H; Arase Y; Chayama K; Kobayashi M; Tsubota A; Koida I; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Miyano Y; Mizoshita K; Matsuda M; Koike H; Hashimoto M
    J Gastroenterol; 1998 Apr; 33(2):223-8. PubMed ID: 9605953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.
    Komatsu F; Takasaki K
    Liver; 1999 Oct; 19(5):375-80. PubMed ID: 10533794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.
    Lu RH; Hwang SJ; Chan CY; Chang FY; Lee SD
    J Clin Lab Anal; 1998; 12(2):121-5. PubMed ID: 9524297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Orito E; Mizokami M
    J Med Virol; 1996 Apr; 48(4):354-9. PubMed ID: 8699168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.
    Shiratori Y; Kato N; Yokosuka O; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Ohkubo H; Arakawa Y; Iwama A; Omata M
    J Hepatol; 1997 Sep; 27(3):437-44. PubMed ID: 9314119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test.
    Yu ML; Chuang WL; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Chang WY
    J Clin Microbiol; 2000 Aug; 38(8):2933-9. PubMed ID: 10921954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.
    Yu ML; Chuang WL; Chen SC; Lin ZY; Hsieh MY; Wang LY; Chang WY
    J Clin Pathol; 1999 Nov; 52(11):807-11. PubMed ID: 10690168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group.
    Pockros PJ; Bain VG; Hunter EB; Conrad A; Balart A; Hollinger FB; Albert D
    J Viral Hepat; 1999 Mar; 6(2):145-50. PubMed ID: 10607226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.